Aggregation Mechanisms and Molecular Structures of Amyloid-β in Alzheimer's Disease

被引:0
|
作者
Niu, Zheng [1 ]
Gui, Xinrui [2 ]
Feng, Shuang [1 ]
Reif, Bernd [3 ,4 ]
机构
[1] Henan Univ, Sch Pharm, Kaifeng 475004, Henan, Peoples R China
[2] St Jude Childrens Res Hosp, Dept Struct Biol, Memphis, TN USA
[3] Tech Univ Munchen TUM, Bavarian NMR Ctr B NMRZ, TUM Sch Nat Sci, Dept Biosci, D-85747 Garching, Germany
[4] Munchen HMGU, Inst Struct Biol STB, Helmholtz Zentrum, D-85764 Neuherberg, Germany
基金
中国国家自然科学基金;
关键词
Alzheimer's disease; amyloid-beta peptide; protein aggregation; liquid-liquid phase separation; solid-state NMR; LIQUID PHASE-SEPARATION; FIBRIL STRUCTURE; ATOMIC STRUCTURES; STRESS GRANULES; ALPHA-SYNUCLEIN; A-BETA(1-42); POLYMORPHISM; PEPTIDE; COMPLEXITY; AMYLOID-BETA(1-42);
D O I
10.1002/chem.202400277
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Amyloid plaques are a major pathological hallmark involved in Alzheimer's disease and consist of deposits of the amyloid-beta peptide (A beta). The aggregation process of A beta is highly complex, which leads to polymorphous aggregates with different structures. In addition to aberrant aggregation, A beta oligomers can undergo liquid-liquid phase separation (LLPS) and form dynamic condensates. It has been hypothesized that these amyloid liquid droplets affect and modulate amyloid fibril formation. In this review, we briefly introduce the relationship between stress granules and amyloid protein aggregation that is associated with neurodegenerative diseases. Then we highlight the regulatory role of LLPS in A beta aggregation and discuss the potential relationship between A beta phase transition and aggregation. Furthermore, we summarize the current structures of A beta oligomers and amyloid fibrils, which have been determined using nuclear magnetic resonance (NMR) and cryo-electron microscopy (cryo-EM). The structural variations of A beta aggregates provide an explanation for the different levels of toxicity, shed light on the aggregation mechanism and may pave the way towards structure-based drug design for both clinical diagnosis and treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Inhibition of Amyloid-β Aggregation in Alzheimer's Disease
    Wang, Qiuming
    Yu, Xiang
    Li, Lingyan
    Zheng, Jie
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (08) : 1223 - 1243
  • [3] Yeast Model of Amyloid-β and Tau Aggregation in Alzheimer's Disease
    Moosavi, Behrooz
    Mousavi, Bibimaryam
    Macreadie, Ian G.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 47 (01) : 9 - 16
  • [4] Phenylethanoids can Modulate Amyloid-β Aggregation Associated with Alzheimer's Disease
    Vance, S. Zeb
    Pate, Kayla
    Moore, Colman
    Moss, Melissa
    BIOPHYSICAL JOURNAL, 2015, 108 (02) : 219A - 219A
  • [5] Amyloid-β induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease
    Cumming, RC
    Schubert, D
    FASEB JOURNAL, 2005, 19 (11): : 2060 - +
  • [6] Norepinephrine Inhibits Alzheimer's Amyloid-β Peptide Aggregation and Destabilizes Amyloid-β Protofibrils: A Molecular Dynamics Simulation Study
    Zou, Yu
    Qian, Zhenyu
    Chen, Yujie
    Qian, Hongsheng
    Wei, Guanghong
    Zhang, Qingwen
    ACS CHEMICAL NEUROSCIENCE, 2019, 10 (03): : 1585 - 1594
  • [7] Arginine and Disordered Amyloid-β Peptide Structures: Molecular Level Insights into the Toxicity in Alzheimer's Disease
    Coskuner, Orkid
    Wise-Scira, Olivia
    ACS CHEMICAL NEUROSCIENCE, 2013, 4 (12): : 1549 - 1558
  • [8] Proposal for an inhibitor of Alzheimer's disease blocking aggregation of amyloid-β peptides: ab initio molecular simulations
    Okamoto, A.
    Nomura, K.
    Yano, A.
    Higai, S.
    Kondo, T.
    Kamba, S.
    Kurita, N.
    IRAGO CONFERENCE 2012, 2013, 433
  • [9] Role of amyloid-β in Alzheimer's disease
    Smith, MA
    Perry, G
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2005, 86 (03) : 131 - 131
  • [10] Intracellular amyloid-β in Alzheimer's disease
    LaFerla, Frank M.
    Green, Kim N.
    Oddo, Salvatore
    NATURE REVIEWS NEUROSCIENCE, 2007, 8 (07) : 499 - 509